3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Burkitt Lymphoma
1
Interventions
pembrolizumab
131
Carboplatin
106
Paclitaxel
66
Cisplatin
61
Gemcitabine
57
Pemetrexed
56
Bevacizumab
50
Docetaxel
47
Fluorouracil
40
Oxaliplatin
38
Dexamethasone
34
130-nm albumin-bound paclitaxel
34
Leucovorin
33
atezolizumab
32
Cetuximab
32
durvalumab
30
Nivolumab
28
Rituximab
26
Cyclophosphamide
26
Capecitabine
26
Prednisone
25
Fulvestrant
24
enzalutamide
23
Lenalidomide
22
venetoclax
21
Letrozole
20
Irinotecan
20
Doxorubicin
17
ribociclib
16
pomalidomide
16
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
siltuximab
×
30 days
×
Clear all
NCT07570173
2026-06-05
MK-1045-005
Merck Sharp & Dohme LLC
Phase 2/3
Recruiting
340 enrolled